Thu.Jun 20, 2024

article thumbnail

STAT+: Gilead’s twice-yearly antiviral protected women from HIV infection in large trial

STAT

Gilead said Thursday that twice-a-year injections of a new antiviral drug, called lenacapavir, completely protected cisgender women from contracting HIV in a large Phase 3 trial. In the study, none of the 2,134 women who received lenacapavir contracted HIV. By comparison, 16 of the 1,068 women who received the long-running daily pill Truvada contracted HIV.

article thumbnail

New data showcase promise, growing pains of CAR-T in autoimmune disease

PharmaVoice

One expert described trial results presented at EULAR last week as “unprecedented.” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.

241
241
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Change Healthcare to begin notifying patients that cyberattack compromised their private info

STAT

Change Healthcare is beginning the process of notifying a “substantial proportion” of Americans that their private information, such as Social Security numbers and medical diagnoses, was compromised in the cyberattack that brought portions of the U.S. health care system to a halt earlier this year. On Thursday, Change will begin to notify health care providers, insurance companies, and other customers that their patients’ data was stolen in the company’s February cybe

363
363
article thumbnail

NIH-funded trials fall flat on diversity goals

PharmaVoice

Many clinical trials aren’t meeting enrollment inclusion checkpoints — and some aren’t even setting targets, according to a recent OIG report.

241
241
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

STAT+: Doctors Without Borders is closing its widely regarded access-to-medicines campaign

STAT

In a surprise move, Doctors Without Borders is closing down its access-to-medicines campaign, which has been credited with ensuring needed drugs and vaccines have been made available to countless patients in low-income countries around the world. The organization plans to close its campaign by the end of this year and create a new effort devoted to access to products for health care.

Vaccines 363
article thumbnail

Two-thirds of pharmacies slash opening hours amid funding pressures

The Pharmacist

Almost two-thirds of pharmacies in England have decreased their opening hours since 2015, latest analysis from the National Pharmacy Association (NPA) has suggested. The research, based on a sample of 110 pharmacies, found that on average there has been a 6.1-hour (10%) reduction in opening hours for every pharmacy. The findings come as up to […] The post Two-thirds of pharmacies slash opening hours amid funding pressures appeared first on The Pharmacist.

More Trending

article thumbnail

Paul Rees: 'We need to keep the pressure up'

The Pharmacist

The Pharmacist caught up with National Pharmacy Association (NPA) chief executive Paul Rees during today's ‘day of action’ to save community pharmacies, at a branch of Green Light Pharmacy in central London. Paul, tell us how the Save Our Pharmacies day of action campaign has been going today? For the first time ever, community pharmacies […] The post Paul Rees: 'We need to keep the pressure up' appeared first on The Pharmacist.

article thumbnail

STAT+: Top FDA official Peter Marks overruled staff, review team to approve Sarepta gene therapy

STAT

For a third time, Sarepta Therapeutics has convinced a top Food and Drug Administration official to overrule the prevailing view of their staff and approve a drug for Duchenne muscular dystrophy. On Thursday evening, the FDA announced it expanded the approval of Elevidys, Sarepta’s Duchenne gene therapy, to cover nearly all patients, regardless of age or wheelchair status, despite the fact that the drug failed a large, Phase 3 trial last year.

article thumbnail

The next frontier: How to use AI-powered analytics for life sciences marketing

pharmaphorum

Discover how AI-powered analytics are revolutionising life sciences marketing. Learn how to leverage these cutting-edge technologies to drive insights and success in the industry.

112
112
article thumbnail

Coalition wages campaign for retractions of Richard Lynn’s racist journal articles

STAT

A coalition of researchers, historians, and journalists is urging that major scientific publishers, including Elsevier and Springer, retract the racist articles of an academic known — and sometimes lauded for — a long career espousing ideas of racial superiority and eugenics. The call for retraction, made Thursday in a First Opinion published in STAT, focuses on hundreds of papers published by the late Richard Lynn of the University of Ulster, who has described “the decay of

362
362
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

FDA lifts hold on PTC Huntington’s disease trial

BioPharma Dive

The agency has lifted a partial trial suspension based on one-year data showing PTC’s pill suppressed a key protein associated with the disorder.

123
123
article thumbnail

STAT+: New immunotherapy combination could ‘change the landscape’ of cancer treatment

STAT

When they work, immunotherapy drugs called checkpoint inhibitors can shrink cancers and, in some cases, eradicate tumors altogether. These drugs, which include Keytruda and Opdivo, are prescribed to hundreds of thousands of patients a year for dozens of different kinds of cancer — but they only work for a minority of them. Most patients ultimately end up progressing or relapsing.

352
352
article thumbnail

Obesity drug from Zealand shows potential in early trial

BioPharma Dive

Interim study data suggest the Danish drugmaker can remain in the race to develop new kinds of weight loss drugs as doctors seek alternatives to the now dominant GLP-1s.

113
113
article thumbnail

Screen early in pregnancy for gestational diabetes, new Lancet series urges

STAT

Gestational diabetes affects one in seven expecting women globally and rates of this troubling condition are rising. Blood glucose levels that become elevated for the first time during pregnancy can lead to severe complications, such as preeclampsia, and increase the risk of stillbirth. And while the condition typically resolves after birth, it is linked to a tenfold increase in the risk of developing type 2 diabetes, along with risks for the child including obesity, cardiovascular disease, and

Diabetes 344
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Twice-yearly shots of Gilead HIV drug effective in large prevention study

BioPharma Dive

Researchers recommended Gilead end testing early as lenacapavir proved 100% effective in protecting cisgender women in the Phase 3 trial.

127
127
article thumbnail

Opinion: Getting ahead of a non-alcoholic beverage boom among youths

STAT

The non-alcoholic beverage market is booming right now : zero-proof bottle shops and bars are popping up across the country ; a non-alcoholic beer brand is even taking over as the top selling beer at Whole Foods. And the Olympic Games have their first beer sponsor , courtesy of alcohol-free Corona Cero. While it’s great that more people are taking to heart public health messages that reducing alcohol consumption can improve well-being and extend life , an important lesson from vaping as a

352
352
article thumbnail

AbbVie breaks new ground for IL-23 drug Skyrizi in IBD

pharmaphorum

AbbVie’s Skyrizi is approved by the FDA for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease.

110
110
article thumbnail

STAT+: Vertex reaches a new deal with NHS England over its pricey cystic fibrosis treatments

STAT

After months of haggling, Vertex Pharmaceuticals and the National Health Service in England reached agreement over access to several cystic fibrosis treatments, capping an end to a long-running saga that frequently enraged patients and families who sought the treatments. Specific details were not released, but the deal was announced after a U.K. cost-effectiveness watchdog decided to recommend the Vertex medicines for coverage by the NHS.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

FDA approves AbbVie’s Skyrizi for UC treatment

Pharmafile

AbbVie has announced that the US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) and moderate to severe Crohn’s disease. The post FDA approves AbbVie’s Skyrizi for UC treatment appeared first on Pharmafile.

105
105
article thumbnail

STAT+: Zealand’s amylin-targeting drug shows early potential in obesity

STAT

Zealand Pharma on Thursday reported early positive results of an investigational obesity drug that activates a hormone that’s not targeted by popular treatments Wegovy and Zepbound. In one part of a Phase 1b study, petrelintide, which targets the amylin hormone, led to 8.6% weight loss at 16 weeks, more than the 1.7% weight loss among patients taking placebo, the Danish company said.

330
330
article thumbnail

Infectious disease group ISID names six global priorities

pharmaphorum

International Society for Infectious Diseases (ISID) publishes six priorities focusing on challenges faced by low- and middle-income countries (LMICs).

114
114
article thumbnail

Lilly takes more actions against unapproved versions of Mounjaro

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning. Here in Chicago, temperatures are high and tensions are even higher as two major hot dog restaurants are  reportedly beefing. Apparently PETA is involved and taunted one of the restaurants with a “pig mobile” even though that restaurant doesn’t even serve pork.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Semi-automation of manual interventions in high-speed filling lines

European Pharmaceutical Review

Researchers have developed a novel, gloveless intervention method with remote robotic interventions for high-speed pharmaceutical isolator filling lines. While these high-speed lines are currently fully automated, Dekker et al. noted that operator interventions are still done manually. For example, a common intervention is the removal of erroneous plungers or stoppers.

105
105
article thumbnail

STAT+: Bold’s CEO on fall prevention, ageism in health care, and ‘movement is medicine’

STAT

BEVERLY HILLS, Calif. – When Amanda Rees was in her twenties she moved in with her grandmother, who was in her 80s, and saw first-hand the issues older adults face with falls and balance. “It really radicalized how I thought about aging,” she said. Serving as her grandmother’s caretaker inspired her to shift into health care and start Bold , a health tech startup that provides at-home digital exercise programs targeted at adults 65 and older.

Hospitals 312
article thumbnail

Sanofi: NICE would reject Sarclisa even if it cost nothing

pharmaphorum

After rejection of its multiple myeloma therapy Sarclisa by NICE, Sanofi claims the drug would not have been deemed cost-effective 'even at zero price'

107
107
article thumbnail

STAT+: A primer on HELIOS-B, an enormous stock-moving event for Alnylam Pharmaceuticals

STAT

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up  here  to get it delivered every Thursday to their inbox. The outcome of the HELIOS-B study — expected at the end of June or early July — is an enormous stock-moving event for Alnylam Pharmaceuticals. Billions of dollars in potential revenue — sufficient to power Alnylam into profitability — are on the line.

315
315
article thumbnail

Yellowstone Biosciences launches to develop soluble bispecific cancer therapies

Pharmaceutical Business Review

The company will develop these therapies to target human leukocyte antigen (HLA) Class II (HLA-II) in oncology field. The funding will support Yellowstone in its operational build, progression of its lead programme for the treatment of acute myeloid leukaemia (AML), and potential expansion of its pipeline. It was spun out of the University of Oxford with the backing of Oxford University Innovation (OUI).

102
102
article thumbnail

STAT+: Pharmalittle: We’re reading about Lilly lawsuits, Novo Nordisk fires and much more

STAT

Rise and shine, everyone, another hot day is on the way. The forecast – at least on this side of the pond – is warning us to find some shade. So to prepare, we are grabbing a parasol and, naturally, brewing a few cups of stimulation to see us through. Our choice today is orange creme. No matter the weather, though, there is work to be done.

Diabetes 295
article thumbnail

The Intricate Journey of Drug Patents: From Filing to Expiry

Drug Patent Watch

In the high-stakes world of pharmaceuticals, patents play a pivotal role in safeguarding intellectual property and ensuring a return on investment for drug developers. The journey of a drug patent is a complex and intricate one, spanning from the initial filing to its eventual expiry.

article thumbnail

STAT+: Ginkgo Bioworks lays off 158 employees, with more to come

STAT

BOSTON — Ginkgo Bioworks, the once-high-flying Boston life sciences firm, on Thursday said it has notified 158 employees that they will be laid off and expects to announce another batch of layoffs next week. On May 9, Ginkgo said it would slash labor costs by at least 25 percent. But the Boston-based cell programming and biosecurity company declined to specify the number of workers who would be let go.

299
299
article thumbnail

US study suggests BMS’ cancer drug could target Parkinson’s-causing protein

Pharma Times

The progressive neurodegenerative condition affects more than ten million people worldwide

134
134
article thumbnail

Listen: Fauci’s memoir, Alnylam’s tenuous trial, and a mid-year review

STAT

Can Alnylam find success with its latest cardiac treatment after tweaking the trial? And did STAT’s editorial team pull off a covert mission to get an advanced copy of a new book? We cover all that and more on this week’s episode of “The Readout LOUD.” STAT reporter Jason Mast joins us to discuss Anthony Fauci’s memoir “On Call,” which was published this week.

287
287